On This Day in Health: May 15, 2024
On May 15, 2024, the U.S. Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel, sold as Breyanzi, for adults with relapsed or refractory follicular lymphoma after two or more previous lines of systemic therapy. The decision expanded the uses of an existing CAR T-cell treatment rather than introducing the product for the first time. Follicular lymphoma is a blood cancer for which disease can return or stop responding after treatment. The new indication offered another option for a defined group facing that situation, while retaining the demanding preparation and safety requirements associated with cellular therapy.
CAR T-cell treatment uses a patient's own immune cells as the basis of the medicine. T cells are collected and modified to carry receptors that recognize a target on cancer cells. The altered cells are then expanded and returned to the patient. Breyanzi targets CD19, a protein associated with B cells. This process differs from giving a standard manufactured tablet or conventional chemotherapy alone: the treatment depends on individualized cell collection, laboratory processing and coordination with the clinical team. Patients also receive preparatory treatment before the cells are administered. The possibility of a sustained response comes with a complex journey through specialist services.
The approval was supported by the TRANSCEND-FL study in previously treated follicular lymphoma. Researchers measured response and its duration, with an independent review of the findings. The FDA reported a high response rate in the main efficacy population, but that result should not be read as a guarantee for every patient or as proof that the disease can never return. The accelerated pathway required further work to verify clinical benefit. Important risks included cytokine release syndrome and neurologic toxicity, conditions that can become life-threatening. The original approval therefore included specialized risk-management requirements. Careful monitoring was part of delivering the therapy, not merely an administrative detail surrounding it.
May 15 records an expansion of the role of engineered immune cells in treating blood cancer. It also illustrates why an approval for one lymphoma cannot be assumed to cover every related diagnosis or every stage of treatment. The type of disease, previous therapies and the evidence supporting a particular indication all matter. For patients whose cancer had persisted through earlier treatment, the decision enlarged the range of options that a specialist team could consider. Its historical significance lies in that opportunity and in the continuing effort to make cellular therapy effective, manageable and accessible. The anniversary recognizes progress while preserving the limits and practical responsibilities attached to the 2024 decision.
The new indication covered follicular lymphoma after at least two prior treatment lines.
Breyanzi was already approved for other blood-cancer uses.
The therapy modifies a patient's T cells to recognize CD19.
TRANSCEND-FL supplied the response evidence supporting accelerated approval.
Cytokine release syndrome and neurologic toxicity required specialist monitoring.
The approval expanded options without guaranteeing a response for every patient.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.